Considerations for use of direct oral anticoagulants in arterial disease
Abstract Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiov...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-05-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rth2.12502 |
| _version_ | 1797721055061606400 |
|---|---|
| author | Deborah M. Siegal Sonia S. Anand |
| author_facet | Deborah M. Siegal Sonia S. Anand |
| author_sort | Deborah M. Siegal |
| collection | DOAJ |
| description | Abstract Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular events. We provide a narrative review of randomized clinical trials evaluating direct oral anticoagulants (DOACs) for the treatment of acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease. In these conditions, considerations for use of single antiplatelet therapy, dual antiplatelet therapy, or low‐dose DOACs used together with antiplatelet therapy are presented. |
| first_indexed | 2024-03-12T09:28:17Z |
| format | Article |
| id | doaj.art-696c118be65a4ed792cbed8612365154 |
| institution | Directory Open Access Journal |
| issn | 2475-0379 |
| language | English |
| last_indexed | 2024-03-12T09:28:17Z |
| publishDate | 2021-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Research and Practice in Thrombosis and Haemostasis |
| spelling | doaj.art-696c118be65a4ed792cbed86123651542023-09-02T14:02:17ZengElsevierResearch and Practice in Thrombosis and Haemostasis2475-03792021-05-0154n/an/a10.1002/rth2.12502Considerations for use of direct oral anticoagulants in arterial diseaseDeborah M. Siegal0Sonia S. Anand1Department of Medicine University of Ottawa Ottawa ON CanadaDepartment of Medicine McMaster University Hamilton ON CanadaAbstract Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular events. We provide a narrative review of randomized clinical trials evaluating direct oral anticoagulants (DOACs) for the treatment of acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease. In these conditions, considerations for use of single antiplatelet therapy, dual antiplatelet therapy, or low‐dose DOACs used together with antiplatelet therapy are presented.https://doi.org/10.1002/rth2.12502acute coronary syndromeanticoagulantsbrain ischemiadirect oral anticoagulantsperipheral arterial diseaseplatelet aggregation inhibitors |
| spellingShingle | Deborah M. Siegal Sonia S. Anand Considerations for use of direct oral anticoagulants in arterial disease Research and Practice in Thrombosis and Haemostasis acute coronary syndrome anticoagulants brain ischemia direct oral anticoagulants peripheral arterial disease platelet aggregation inhibitors |
| title | Considerations for use of direct oral anticoagulants in arterial disease |
| title_full | Considerations for use of direct oral anticoagulants in arterial disease |
| title_fullStr | Considerations for use of direct oral anticoagulants in arterial disease |
| title_full_unstemmed | Considerations for use of direct oral anticoagulants in arterial disease |
| title_short | Considerations for use of direct oral anticoagulants in arterial disease |
| title_sort | considerations for use of direct oral anticoagulants in arterial disease |
| topic | acute coronary syndrome anticoagulants brain ischemia direct oral anticoagulants peripheral arterial disease platelet aggregation inhibitors |
| url | https://doi.org/10.1002/rth2.12502 |
| work_keys_str_mv | AT deborahmsiegal considerationsforuseofdirectoralanticoagulantsinarterialdisease AT soniasanand considerationsforuseofdirectoralanticoagulantsinarterialdisease |